Predicting transporter-based drug clearance (CL) and tissue concentrations (TC) in humans
is important to reduce the risk of failure during drug development. In addition, when …

Pharmacokinetic drug–drug interactions (DDIs) occur when a drug alters the absorption,
transport, distribution, metabolism or excretion of a co-administered agent. The occurrence …

Mechanistic understanding of complex clinical drug–drug interactions (DDI s) with potential
involvement of multiple elimination pathways has been challenging, especially given the …

Quantitative assessment of drug‐drug interactions (DDIs) involving breast cancer resistance
protein (BCRP) inhibition is challenged by overlapping substrate/inhibitor specificity. This …

The occurrence of drug–drug interactions (DDIs) can significantly affect the safety of a
patient, and thus assessing DDI risk is important. Recently, physiologically based …

Organic solute transporter alpha/beta (OSTα/β) is a heteromeric solute carrier protein that
transports bile acids, steroid metabolites and drugs into and out of cells. OSTα/β protein is …

The incidence of acute kidney injury in the elderly has grown over the past decade. One of
the primary drivers is drug-induced nephrotoxicity, which is the result of a combination of the …

Introduction: ABCG2 has a broad substrate specificity and is one of the most important efflux
proteins modulating pharmacokinetics of drugs, nutrients and toxicokinetics of toxicants …

The heteromeric steroid transporter organic solute transporter α/β (OSTα/β, SLC51A/B) was
discovered over a decade ago, but its physiological significance in the liver remains …

Renal clearance is usually predicted via empirical approaches including quantitative
structure activity relationship and allometric scaling. Recently, mechanistic prediction …